<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(1)</volume><submitter>Soares T</submitter><funding>International Parkinson and Movement Disorder Society</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>The MDS-UPDRS has been available in English since 2008, showing satisfactory clinimetric results and being proposed as the new official benchmark scale for Parkinson's disease (PD), being cited as a core instrument for PD in the National Institutes of Neurological Disorders and Stroke Common Data Elements program. For this reason, the MDS created guidelines for development of MDS-UPDRS official, clinimetrically validated translations.&lt;h4>Objective&lt;/h4>This study presents the formal process used to obtain the officially approved Portuguese version of the MDS-UPDRS.&lt;h4>Methods&lt;/h4>The study consisted of three phases: (1) Independent translation by Portuguese and Brazilian teams followed by a challenging consensus process that this article particularly emphasizes; (2) Cogni</pubmed_abstract><journal>Movement disorders clinical practice</journal><pagination>34-42</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11736879</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Validation of the Portuguese MDS-UPDRS: Challenges to Obtain a Scale Applicable to Different Linguistic Cultures.</pubmed_title><pmcid>PMC11736879</pmcid><pubmed_authors>Borges V</pubmed_authors><pubmed_authors>Antunes AP</pubmed_authors><pubmed_authors>Vila-Cha N</pubmed_authors><pubmed_authors>Camargos ST</pubmed_authors><pubmed_authors>Barbosa R</pubmed_authors><pubmed_authors>Silva SA</pubmed_authors><pubmed_authors>Alves J</pubmed_authors><pubmed_authors>Barbosa ER</pubmed_authors><pubmed_authors>Sequeira J</pubmed_authors><pubmed_authors>Stebbins GT</pubmed_authors><pubmed_authors>Valadas A</pubmed_authors><pubmed_authors>Godinho C</pubmed_authors><pubmed_authors>Maia R</pubmed_authors><pubmed_authors>LaPelle NR</pubmed_authors><pubmed_authors>Bezerra TC</pubmed_authors><pubmed_authors>Coelho M</pubmed_authors><pubmed_authors>Lobo P</pubmed_authors><pubmed_authors>Canica V</pubmed_authors><pubmed_authors>Maia D</pubmed_authors><pubmed_authors>Medeiros MS</pubmed_authors><pubmed_authors>Santos AF</pubmed_authors><pubmed_authors>Maciel RO</pubmed_authors><pubmed_authors>Costa MM</pubmed_authors><pubmed_authors>Calado A</pubmed_authors><pubmed_authors>Queimado F</pubmed_authors><pubmed_authors>Sallem FAS</pubmed_authors><pubmed_authors>Maciel ROH</pubmed_authors><pubmed_authors>Teodoro T</pubmed_authors><pubmed_authors>Vieira S</pubmed_authors><pubmed_authors>Guedes L</pubmed_authors><pubmed_authors>Tumas V</pubmed_authors><pubmed_authors>Morgado J</pubmed_authors><pubmed_authors>Machado C</pubmed_authors><pubmed_authors>Martins J</pubmed_authors><pubmed_authors>Goetz CG</pubmed_authors><pubmed_authors>Cury RG</pubmed_authors><pubmed_authors>Maia RD</pubmed_authors><pubmed_authors>Guedes LC</pubmed_authors><pubmed_authors>Velon AG</pubmed_authors><pubmed_authors>Saba RA</pubmed_authors><pubmed_authors>Brito MMC</pubmed_authors><pubmed_authors>Alegria P</pubmed_authors><pubmed_authors>Simoes R</pubmed_authors><pubmed_authors>Mendes A</pubmed_authors><pubmed_authors>Santos-Lobato BL</pubmed_authors><pubmed_authors>Barcelos LB</pubmed_authors><pubmed_authors>de Mello Rieder CR</pubmed_authors><pubmed_authors>Varandas S</pubmed_authors><pubmed_authors>Ferreira JJ</pubmed_authors><pubmed_authors>Maia DP</pubmed_authors><pubmed_authors>Limongi JCP</pubmed_authors><pubmed_authors>de Oliveira DS</pubmed_authors><pubmed_authors>Veiga A</pubmed_authors><pubmed_authors>da Silva CC</pubmed_authors><pubmed_authors>Soares T</pubmed_authors><pubmed_authors>Rieder C</pubmed_authors><pubmed_authors>Cunha C</pubmed_authors><pubmed_authors>Massano J</pubmed_authors><pubmed_authors>Vale J</pubmed_authors><pubmed_authors>Novaretti N</pubmed_authors><pubmed_authors>Cunha ALN</pubmed_authors><pubmed_authors>Rosas MJ</pubmed_authors><pubmed_authors>Ferraz HB</pubmed_authors><pubmed_authors>Lampreia T</pubmed_authors><pubmed_authors>Rodrigues AM</pubmed_authors><pubmed_authors>MDS‐UPDRS Portuguese Validation Study Group</pubmed_authors><pubmed_authors>Dias S</pubmed_authors><pubmed_authors>Vale TC</pubmed_authors><pubmed_authors>Camargos S</pubmed_authors><pubmed_authors>Cardoso F</pubmed_authors><pubmed_authors>Barbosa E</pubmed_authors><pubmed_authors>Tilley BC</pubmed_authors><pubmed_authors>Luo S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Validation of the Portuguese MDS-UPDRS: Challenges to Obtain a Scale Applicable to Different Linguistic Cultures.</name><description>&lt;h4>Background&lt;/h4>The MDS-UPDRS has been available in English since 2008, showing satisfactory clinimetric results and being proposed as the new official benchmark scale for Parkinson's disease (PD), being cited as a core instrument for PD in the National Institutes of Neurological Disorders and Stroke Common Data Elements program. For this reason, the MDS created guidelines for development of MDS-UPDRS official, clinimetrically validated translations.&lt;h4>Objective&lt;/h4>This study presents the formal process used to obtain the officially approved Portuguese version of the MDS-UPDRS.&lt;h4>Methods&lt;/h4>The study consisted of three phases: (1) Independent translation by Portuguese and Brazilian teams followed by a challenging consensus process that this article particularly emphasizes; (2) Cogni</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan</publication><modification>2026-06-05T04:54:19.544Z</modification><creation>2026-05-13T14:28:44.01Z</creation></dates><accession>S-EPMC11736879</accession><cross_references><pubmed>39460979</pubmed><doi>10.1002/mdc3.14236</doi></cross_references></HashMap>